Growth Hormone Fragment

AOD-9604

Anti-Obesity Drug 9604 • HGH Fragment 176-191 Analog

AOD-9604 is a stabilized synthetic growth hormone fragment researched for fat mobilization. It has unusually strong safety data across human trials, but its largest obesity trial failed to show statistically significant weight loss versus placebo.

Fat Mobilization Strong Safety Data Weak Efficacy Data WADA Prohibited

Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

AOD-9604

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Standard Dose

300mcg

Once daily, morning fasted, subcutaneous injection.

Cycle

4–12 Weeks

Best paired with fasting windows and fasted training.

Route

SubQ

AOD-9604 is typically used as a subcutaneous injection.

Higher Dose

500mcg

Once daily or split 250mcg AM + 250mcg before bed.

Peptide Grade

GradeC

Targeted fat-loss concept is practical, but results and evidence are inconsistent. Safety data is strong; obesity-trial efficacy is weak.

Strong Safety Weak Efficacy WADA Prohibited

Best framed as a low-risk, low-impact fat-loss adjunct rather than a primary fat-loss solution.

Foundation

Research context, mechanisms, and practical use cases

What Is AOD-9604?

AOD-9604 stands for Anti-Obesity Drug 9604. It is a synthetic peptide consisting of 16 amino acids derived from the tail end of human growth hormone, specifically amino acids 176 through 191 with a tyrosine substitution at the N-terminus to stabilize the molecule.

The idea behind it was straightforward. Growth hormone is one of the most powerful fat-burning hormones in the body, but it comes with a list of side effects: insulin resistance, water retention, elevated IGF-1, carpal tunnel, and in extreme cases organ growth. Researchers at Monash University in Australia asked a smart question: what if you could isolate just the fat-burning piece and strip away everything else?

So they cut out those C-terminal amino acids and engineered a standalone fragment that, in theory, would give you the lipolytic benefit of growth hormone without the downsides.

Clinical Development Summary

AOD-9604 completed six human clinical trials with over 900 participants. The safety data was consistently excellent, but the weight loss results were underwhelming. The largest Phase 2b trial, the OPTIONS study with 536 obese adults over 24 weeks, failed to achieve statistically significant weight loss versus placebo. Metabolic Pharmaceuticals terminated the obesity program in 2007.

Despite that clinical failure, AOD-9604 remains widely available through research peptide suppliers and TRT clinics. The safety profile makes it low-risk to sell, the cost is low, the name sounds clinical and intentional, and it received GRAS status for food applications. But being safe and being effective are two different questions. The safety data is strong. The efficacy data for fat loss in humans is not.

You will also see HGH Fragment 176-191 sold online as though it is the same compound. It is related but not identical. AOD-9604 is the engineered, more stable version with the tyrosine substitution. If the more stable version could not beat placebo in its biggest trial, the raw fragment starts from an even weaker position.

AOD-9604 Benefits

The benefits section for AOD-9604 is shorter than for most compounds in this course because the clinical evidence for its primary marketed benefit, fat loss, is weak.

Safety Profile

This is the strongest thing AOD-9604 has going for it. Over 900 participants across six human clinical trials, and it was consistently well-tolerated.

No IGF-1 Impact

AOD-9604 did not increase IGF-1 levels across trials, unlike full growth hormone or secretagogues.

No Metabolic Disruption

Clinical data did not show elevated blood sugar, insulin resistance, or meaningful changes in clinical biomarkers.

Potential Cartilage Support

Animal research suggests intra-articular AOD-9604 may support cartilage regeneration, especially with hyaluronic acid.

Low Cost

Compared to GLP-1 drugs, growth hormone, or secretagogues, AOD-9604 is inexpensive.

Fat-Loss Edge Only

If it works, the effect is best thought of as a subtle edge, not a primary fat-loss solution.

Protocol Planning

Dosing, reconstitution, and practical use

AOD-9604 Dosing Protocol

Standard Protocol

Dose

300mcg once daily

Frequency

Once daily

Timing

First thing in the morning, fasted

Route

Subcutaneous injection

Wait

At least 30 minutes before eating

Duration

4 to 12 weeks

Higher Dose Protocol

Dose

500mcg once daily

Timing

Morning, fasted

Split

Some users split 250mcg morning + 250mcg before bed

Duration

4 to 12 weeks

Fasting is Critical

Morning dosing is most common because it aligns with the natural fasted state. AOD-9604 is a fat mobilizer and works best with long fasting windows before and after dosing, generally in the 2–3 hour range. Ideal scenario: fast overnight, dose, fast another 2–3 hours, and fit your workout in before eating.

AOD-9604 Reconstitution

AOD-9604 is notoriously finicky with reconstitution and users frequently complain about gelling. To help prevent this, purchase smaller vial sizes such as 5 mg or less. Only use Hospira BAC water. You can also buy specific “AOD water” designed to prevent gelling.

Do not use bacteriostatic water by itself for AOD-9604. Combine with 0.6% acetic acid solution.

Preferred Method

Solvent

0.5mL of 0.6% acetic acid solution + 2mL Hospira BAC water

Order

Add the acetic acid first

Technique

Add slowly down the inside wall of the vial. Do not spray directly on the powder.

Handling

Do not shake. Let the powder dissolve on its own. Swirl gently if needed.

Reconstitution Calculator

Alternative Method

Solvent

1mL 0.6% acetic acid + 1mL Hospira BAC water

Order

Add the acetic acid first

Technique

Add slowly down the vial wall and allow passive dissolution.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Some users report subtle belly-fat reduction over 6–12 weeks when diet, fasting, and training are already consistent.
AOD-9604 appears better suited as a small edge for users who already have diet, fasting, and training dialed in.
AOD-9604 is often added to CJC-1295/Ipamorelin or Tesamorelin protocols even though growth hormone release is already performing lipolytic work.

Negative Reports

Many users report no noticeable change, especially when expecting dramatic or standalone fat loss.
Gelling, clumping, and visible aggregation are among the most common practical complaints.
Individual results appear strongly dependent on calorie control, fasting duration, training consistency, and starting body composition.

Stacking & Synergy

Potential AOD-9604 pairings and tracking context

These pairings are mechanistic or community-discussed combinations rather than validated AOD-9604 combination protocols. Several growth-hormone stacks may be redundant.

AOD-9604 + CJC-1295/Ipamorelin

Generally redundant. A GH secretagogue already releases actual growth hormone, which performs direct lipolysis and converts to IGF-1.

AOD-9604 + Tesamorelin

Also redundant in most cases. Tesamorelin activates a broader and more complete growth hormone pathway.

AOD-9604 + GLP-1 Agonists

Different mechanisms and no timing conflicts. GLP-1 agonists do the heavy lifting through appetite and central metabolic signaling.

AOD-9604 + Training/Fasting

Best practical use case is fasted morning dosing with training before the first meal.

Why I Generally Do Not Recommend AOD-9604 in GH Stacks

Adding AOD-9604 on top of a secretagogue stack is paying extra money for a fragment of a process that is already happening from the secretagogue, and the secretagogue does it better because it triggers the complete growth hormone cascade.

Free with login

Track in Journal

Track AOD-9604 with the markers that matter most for this compound: weight, waist, fasting window, training, injection-site response, and sleep.

Dose, timing, cycle day, and fasting window.
Weight, waist, and standardized progress photos.
Fasted training and nutrition consistency.
Injection-site response, gelling, and reconstitution issues.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

AOD-9604 Side Effects

Clinical trial data across six human studies showed a side-effect profile that was indistinguishable from placebo. No significant adverse events, no withdrawals attributed to the compound, and no clinically meaningful biomarker changes were reported.

Non-clinical toxicology studies lasting up to nine months in monkeys found no treatment-related deaths, clinical toxicity, organ pathology, genotoxicity, or immunogenicity at doses far above those commonly used in practice.

AOD-9604 has unusually strong safety data for a research peptide, but safety does not establish meaningful fat-loss efficacy.

Not Observed in Trials

No elevated blood sugar or insulin resistance.
No increase in IGF-1.
No water retention, joint pain, or carpal tunnel symptoms.
No meaningful sleep disruption in clinical research.

Occasional User Reports

Injection-site redness or mild irritation.
Mild headache.
Mild nausea or indigestion.
Practical issues related to gelling or poor reconstitution.

AOD-9604 Contraindications and Precautions

Use With Caution If You Have

Active cancer or history of cancer. Though AOD-9604 does not raise IGF-1, the overall lack of long-term human data warrants caution with any peptide compound.
Pregnancy or breastfeeding, because no safety data exists for these populations.
Known hypersensitivity to AOD-9604 or related growth hormone fragments.

Drug Interactions

No significant drug interactions have been identified across clinical trials.

Athletes

AOD-9604 is on the WADA prohibited list under S2.2.3 as a growth hormone fragment. It is banned by all major sporting organizations including the UFC, NFL, NCAA, NHL, MLB, NAIA, and PGA.

If you compete in tested sports, do not use this compound.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

AOD-9604 might just be the most hated-on compound out there. The red headed step child of the peptide world. The complaints litter community forums with everything from it sucks, it doesn't work, or the damn thing gelled. We get it and these people aren't necessarily wrong. Even the Phase 2 trials were cancelled as they did not meet the primary efficacy endpoint. No statistically significant difference in weight loss or fat loss versus placebo at any dose. So why are we about to recommend it? Hear us out...

Lets start with the main problem, which is that researchers have used this compound incorrectly the entire time. AOD-9604 is a fat mobilizer, not a fat burner. If you don't implement intermittent fasting and or combine it with an active gym heavy lifestyle, it's not going to move the needle. It unlocks the fat door, but you have to use it. If you are sedentary it is just not going to work and you wasted money. Secondly, it must be used alongside a GLP-1, any of them. AOD-9604 unlocks the fat door and the GLPs do their work creating a very nice synergestic approach.

To be clear, AOD-9604 is what we'd call an add-on to increase desired fat loss results, not to be the primary weight loss driver. We'd recommend it for anyone doing a cut and trying to lose the last little bit of fat. When you combine the clean safety profile in the human trials (hundreds of participants across Phase 1/2 studies without any red flags), plus AOD-9604 being a high maintenance peptide that requires some acidic acid for reconstitution, not to mention a large fasting window, the C grade holds true.